BioSpace News Archive

Roswell Park trial identifies small, critical protein involved in anticancer immune response

GeoVax Labs, Inc. announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will deliver a talk during the 12th Vaccine Congress, organized by Elsevier and Vaccine journal, being held September 16-19, 2018 in Budapest, Hungary.

Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s Bifunctional Activity Inhibiting Both the Complement and Leukotriene Inflammatory Pathways

BTX 1503 acne Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019

Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering.

Octapharma USA Partners with GutMonkey To Provide Hemophilia Patients Life-Changing Adventure Experience

Vision Research, a leading manufacturer of digital high-speed imaging systems, is pleased to announce a partnership with Love High Speed that grants exclusive rights to rent the new Phantom® v2640 Onyx within Europe and the Middle East.

Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s Bifunctional Activity Inhibiting Both the Complement and Leukotriene Inflammatory Pathways

IPH5401 is a first-in-class antibody targeting the C5a receptor expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment

Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).